ClinicalTrials.gg
CompletedNCT00640809Updated Feb 2, 2021

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

A Phase 4 interventional study of Celecoxib and Placebo in Bowel Diseases, Inflammatory, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
26th of 327
408 · median 50
Started
2003
with 4 others
Phase 4
31 of 463
3 open now
Registered
50th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 26th largest by enrollment of the 327 interventional ones that give a count, is one of 5 that started in 2003, is one of 31 in phase 4, and was the 50th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole

03

Conditions studied

  • Bowel Diseases, Inflammatory

Keywords

  • Bowel Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria:

  • Normal, healthy gastrointestinal tract (no small bowel mucosal breaks at Day 14 according to endoscopic data
  • No history of GI ulcers, bleeding or surgery, or complete or partial stenosis of the small intestine
  • Willing not to drink any alcohol during study period

Exclusion Criteria:

Exclusion criteria:

  • Has established delayed gastric emptying or diabetic gastroparesis
  • Has active gastroesophageal reflux disease or requires anti-ulcer medications
  • Has taken aspirin or nonsteroidal antinflammatory drugs (ibuprofen, naproxen) more than 3 times per week within 2 weeks prior to the screening visit; aspirin for cardiovascular prophylaxis is restricted
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Placebo comparator
    B

    Other: Placebo

  • Active comparator
    C

    Drug: Ibuprofen plus Omeprazole

Interventions

  • 200 mg oral capsule twice daily for 2 weeks

  • OtherPlacebo

    Matched placebo for 2 weeks

  • DrugIbuprofen plus Omeprazole

    Drug pages: Ibuprofen · Omeprazole

    ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks

06

What researchers measure

Primary outcomes

  1. Number of mucosal breaks in the small bowel for each subject

    Time frame: Day 30

Secondary outcomes

  1. Adverse events

    Time frame: Day 30

  2. Laboratory tests

    Time frame: Day 30

  3. Vital signs

    Time frame: Day 30

  4. Correlation of number of mucosal breaks in the small bowel for each patient with the result of the fecal calprotectin test

    Time frame: Day 30

  5. Percentage of subjects with gastric mucosal breaks and the number of mucosal breaks

    Time frame: Day 30

  6. Change from screening visit in hemoglobin and hematocrit

    Time frame: Day 30

  7. Correlation of the number of gastric mucosal breaks with the number of small bowel mucosal breaks

    Time frame: Day 30

  8. Physical examination

    Time frame: Day 30

  9. Percentage of subjects with >=1 mucosal breaks

    Time frame: Day 30

  10. Total number of small bowel lesions with or without hemorrhage

    Time frame: Day 30

  11. Percentage of subjects with visible blood in the small bowel (without visualized lesions in the small bowel)

    Time frame: Day 30

  12. Change in Patient General Questionnaire Visual Analog Scale from Day 16

    Time frame: Day 30

  13. Change in Severity of Dyspepsia Assessment questionnaire from Day 16

    Time frame: Day 30

07

Study locations

12 sites
  • Pfizer Investigational Site
    Scottsdale, Arizona 85259, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Jupiter, Florida 33458, United States
  • Pfizer Investigational Site
    Miami, Florida 33173, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Rockford, Illinois 61107, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109-0362, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232-5280, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2008
First posted
Mar 21, 2008
Start
Oct 2003
CompletionActual
Apr 2004
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00640809
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Oct 2003
Completion
Apr 2004
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion